This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SEP-227162

Sumitomo Dainippon Pharma Co., Ltd.

Drug Names(s): SEP-162

Description: SEP-227162 is a serotonin and norepinephrine reuptake inhibitor (SNRI). Serotonin and norepinephrine are two neurotransmitters that are thought to play important roles in the pathophysiology of depression.

Deal Structure: SEP-227162 was originally developed by Sepracor.

In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share. The acquisition was completed in October 2009.


SEP-227162 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug